CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

NCT06947460 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Refractory Lupus Nephritis
Systemic Sclerosis
Primary Sjogren's Syndrome Combined With Pulmonary Hypertension

Interventions

DRUG: CD19-BCMA CAR-T cells infusion

Sponsor

Beijing GoBroad Hospital